Company intelligence / Profile preview

Action Pharma A

Aarhus, Denmark

Ownership: Private
Development stage: Other

Overview

Action Pharma was a Danish clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for inflammatory and metabolic diseases. The company's primary research centered on melanocortin receptor agonists, which target specific pathways to reduce organ damage and improve metabolic function. Its lead candidate, AP214, was developed to prevent acute kidney injury associated with major cardiac surgery. In 2012, the company's lead program was acquired by Abbott Laboratories (now AbbVie) for $110 million, effectively transitioning its primary assets to a global pharmaceutical leader.

Therapeutic areas: ImmunologyEndocrinologyNephrology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Abbott Laboratories

Beyond the preview

Go deeper on Action Pharma A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Action Pharma A.

Explore the full profile